trending Market Intelligence /marketintelligence/en/news-insights/trending/Y8wNE2pkH0Q8LJ0PK8Mnag2 content esgSubNav
In This List

Japan's Terumo fiscal Q1 profit climbs 26% YOY

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Japan's Terumo fiscal Q1 profit climbs 26% YOY

Terumo Corp. said profit attributable to owners of the parent for the first quarter ended June 30 totaled ¥22.79 billion, a gain of 26% from ¥18.09 billion in the prior-year period.

EPS came in at ¥30.15, a 26.1% yearly increase from ¥23.91.

Revenue rose 6.6% year over year to ¥152.53 billion from ¥143.02 billion.

For fiscal year ending March 2020, the Japanese medical device maker expects profit attributable to owners of the parent to reach ¥81 billion, and revenue amounting to ¥635 billion.

Tokyo-based Terumo develops, manufactures and distributes medical devices and services worldwide.

As of Aug. 7, US$1 was equivalent to ¥105.70.